Navigation Links
Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Date:9/4/2007

n of relapsed patients who receive other second-line chemotherapy," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "These results are promising because patients with platinum-resistant and -refractory small cell lung cancer have very limited treatment options. They typically experience rapid disease progression and low overall survival following treatment with existing chemotherapies, which have significant toxicities."

The updated picoplatin Phase 2 data were presented during a poster discussion session at the International Association for the Study of Lung Cancer's (IASLC) 12th World Conference on Lung Cancer in Seoul, Korea.

Additional Phase 2 Study Findings

In addition to the overall and one-year survival findings, the updated analysis of results from the open-label, multi-center Phase 2 trial showed that the disease control rate was 48.1 percent in the 77 evaluable patients. This is similar to that observed with currently available treatments, but with a more manageable side effect profile and less frequent administration. At the time of the updated analysis, 63 patients had died from disease progression. The most common side effects were hematologic and included thrombocytopenia, anemia and neutropenia. No grade 3 or 4 neurotoxicity or nephrotoxicity and no treatment-related deaths occurred.

Pivotal Phase 3 SPEAR Trial Design

Poniard's ongoing international, multi-center, randomized, controlled SPEAR trial is comparing picoplatin plus best supportive care to best supportive care alone to evaluate the efficacy of picoplatin after relapse. Best supportive care includes care and treatment to optimize the comfort of patients and their ability to function, as well as to minimize the side effects of palliative cancer treatments. The primary efficacy endpoint is overall survival, with overall response rates, progression-free survival and disease control also being evaluated. The trial, which is enrolling patients who are refract
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Quantum Materials Corporation ... sets of patent families from Bayer Technology Services GmbH, ... for Bayer AG of Leverkusen, Germany ... provide broad intellectual property protection for advances ... quantum dot (QD) manufacturing. In addition, the Bayer ...
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
Breaking Medicine Technology:Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Information Systems ("SIS"), a leader in perioperative ... leadership in achieving clinical, financial, and operational goals ... the company,s annual client conference, the 2012 SIS ... systems exemplifying the innovative use of information technology ...
... 2012 Top leaders representing America,s advanced medical ... public policy issues affecting job creation and medical innovation and ... billion medical device tax set to begin in January 2013. ... Renacci (R-Ohio) joined Walter M Rosebrough, president and CEO of ...
Cached Medicine Technology:Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 2Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 3Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements 4AdvaMed & BioOhio Discuss MedTech Impact on Ohio's Economy, Job Creation 2AdvaMed & BioOhio Discuss MedTech Impact on Ohio's Economy, Job Creation 3
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 If old ... found a cure for it. With extensive research on HGH ... named ‘MetroMD’ claims to have perfected the art of rubbing ... a brand new younger look with their revolutionary anti-aging hormone ... of the 21st century fountain of youth, the MD of ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... a five-year, $1.24 million Science Education Partnership Award ... to support NAHN’s collaborative project with the Hispanic ... Health Careers. , This collaborative NIH R25 program ... cultural and linguistic diversity among health professionals by ...
(Date:8/20/2014)... Utah (PRWEB) August 20, 2014 Today, ... new information on open enrollment for 2015. , According ... insurance coming up in November, employees are encouraged to ... seeking coverage in 2015, the open enrollment period will ... During open enrollment 2015 individuals can purchase a new ...
(Date:8/20/2014)... 2014 Attendees of Seedstock’s 3rd Annual ... at Los Angeles’ first multi-faceted food production business incubator ... blossoming 1.5-acre high school campus urban farming operation in ... in the L.A. Art District. , The field trip, ... agriculture, will kick off Seedstock’s “Reintegrating Ag: Local Food ...
(Date:8/20/2014)... MA (PRWEB) August 20, 2014 Verndale ... annual Inc. 500|5000 list; an exclusive list ranking the ... list are ranked according to their yearly percentage revenue ... the 8th time on the Inc. 5000 list where ... Technology Company, Verndale offers its clients a wide range ...
Breaking Medicine News(10 mins):Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 2Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 3Health News:For the 8th Time, Verndale Has Been Honored on the Inc. 5000 List 2
... Inc. (Nasdaq: CADX ) announced today that it ... a private placement approximately 12 million shares of the Company,s ... million additional shares of the Company,s common stock, for aggregate ... paid for the common stock, $7.13 per share, is equal ...
... 4:00 PM ET - VALENCIA, Calif., Feb. 17 /PRNewswire-FirstCall/ ... ) today reported financial results for the fourth quarter ... of 2008, total operating expenses were $81.8 million, compared ... Research and development (R&D) expenses increased by $2.0 million ...
... bulk of cases, study finds, , , TUESDAY, Feb. 17 (HealthDay ... loss also have eye disorders, a new study has found. ... ear or to the nerves that link the ear to ... according to background information in the study. Half of all ...
... announced today that it has,received certification of its full ... Standards by the Jefferson School of,Population Health. , ... 10 Quality and Safety Standards in,March of 2007 with ... as its Clinical Advisory Board. A condition of CCA,membership ...
... HotHead Technologies, Inc. today,announced that the technology they ... Kennesaw State University researchers as an early,warning ... "It,s exciting news that research from a university as ... verify much earlier than we anticipated, in,the preliminary stages ...
... Light Press, LLC announces the audio edition of "That,s ... written by co-authors Lil Ingram and Marlene Lee, and ... of HOPE is available in MP3 format at no ... will also be available via the website for the ...
Cached Medicine News:Health News:Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock 2Health News:Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock 3Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:Eye Problems, Hearing Loss May Be Linked 2Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 2Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 3Health News:RediClinic Meets Strict Quality and Safety Standards for Retail Clinics 4Health News:HotHead Technologies' Heat Sensor Shows Exciting Potential by Kennesaw State University Researchers 2Health News:'That's My Hope' Audio Edition Released 2Health News:'That's My Hope' Audio Edition Released 3
... your expectations with state of the art ... customized to meet the needs of your ... can be upgraded to grow with you. ... database management, it is easy to see ...
... ultimate flexibility by allowing you to determine ... display. Wall-mount anywhere in the room. Further ... laptop, touch screen tablet, industrial PC, desktop ... multi-function patient tower provides more power and ...
... capabilities combined with ease of use make ... its class. Ideal for office or hospital-based ... for Uroflowmetry, cystometry, leak point pressure, or ... available which make the OM-5 flexible enough ...
... combined with ease of use make the ... class. Ideal for office or hospital-based urodynamics, ... Uroflowmetry, cystometry, leak point pressure, or urethral ... which make the OM-5 flexible enough to ...
Medicine Products: